INSIGHTS ON DRUG DEVELOPMENT

• Overcoming Food Effects, Variability, Solubility For A Non-Opioid Analgesic With Lipid-Based Formulations

  Develop optimized lipid-based formulations to overcome solubility, stability, and food-effect challenges, enabling high-dose oral delivery and rapid progression to Phase 1 trials.

• Patented Process For Intermediates Useful For Deucravacitinib

  Discover how this patented synthetic approach to Deucravacitinib intermediates can improve yield, simplify purification, and support scalable, regulatory-aligned manufacturing.

• Chirality In Drug Development: From Racemic Mixtures To Enantiopure Substances

  Chiral crystallization enables efficient production of enantiopure drug substances, improving pharmacological control and safety while supporting scalable, cost‑effective small molecule development.

• qPCR Amplification Of Human Gastrointestinal Samples

  Residual inhibitors in GI-derived DNA can hinder qPCR performance. An optimized approach improves inhibitor tolerance and enables earlier target detection, delivering more reliable amplification.

• Spray Dried Biologics For Pulmonary Dosage Forms

  5/8/2026

  View how spray drying enables stable, precisely engineered pulmonary powders for biologics, supporting efficient lung delivery, scalability, and preservation of molecular structure and activity.

• The Role Of CDMOs In Supporting Generic Drug Development

  7/15/2025

  Bringing complex generics to market requires deep expertise. Learn how a CDMO can help navigate regulatory, technical, and commercial challenges with end-to-end development and manufacturing support.

• Driving Operator Safety And Process Efficiency

  10/14/2025

  Discover how ergonomic design and workflow simplification can turn routine production tasks into strategic advantages, as well as practical ways to boost safety, efficiency, and innovation.

• Method Development For Forced Degradation Of GLP-1 Agonist

  3/18/2026

  Gain insight into how a systematic approach reveals impurity behavior, strengthens selectivity, and refines chromatographic conditions to build a reliable degradation method for a GLP‑1 agonist.

• Developing Non-PEG Stabilizer Lipids For Nucleic Acid Lipid Nanoparticles

  7/1/2026

  Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.